84
Participants
Start Date
December 31, 2004
Primary Completion Date
March 31, 2008
Study Completion Date
March 31, 2008
Enfuvirtide
Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.
Optimized background antiretroviral regimen (OB)
Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.
Marseille
Marseille
Marseille
Aix-en-Provence
Marseille
Caen
Besançon
Quimper
Nîmes
Toulouse
Toulouse
Auch
Bordeaux
Bordeaux
Pessac
Montpellier
Rennes
Tours
Nantes
Orléans
Angers
Saint-Dizier
Vandœuvre-lès-Nancy
Valenciennes
Boulogne
Pau
Perpignan
Strasbourg
Colmar
Lyon
Lyon
Mâcon
Rouen
Annecy
Paris
Paris
Paris
Paris
Paris
Paris
Paris
Paris
Lagny-sur-Marne
Mantes-la-Jolie
Niort
Toulon
Carpentras
Avignon
La Roche-sur-Yon
Corbeil-Essonnes
Suresnes
Levallois-Perret
Garches
Bobigny
Saint-Denis
Aulnay-sous-Bois
Créteil
Villejuif
Argenteuil
Pontoise
Basse-terre
Pointe à Pitre
Fort-de-france
Cayenne
Cayenne
Matoury
Saint-Denis
Saint-Pierre
Kourou
Bourg-en-Bresse
Nice
Hoffmann-La Roche
INDUSTRY